The handle http://hdl.handle.net/1887/22544 holds various files of this Leiden University dissertation

Author: Speksnijder, Niels
Title: Determinants of psychosis vulnerability: focus on MEF2- and glucocorticoid signaling
Issue Date: 2013-11-28
Chapter 2 | Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?
Psychosis susceptibility is mediated in part by the dopaminergic neurotransmitter system. In humans there are individual differences in vulnerability for psychosis which are reflected in differential sensitivity for psychostimulants such as amphetamine. We hypothesize that the same genes and pathways underlying behavioral sensitization in mice are also involved in the vulnerability to psychosis. The aim of the current study was to investigate which genes and pathways may contribute to behavioral sensitization in different dopaminergic output areas in the mouse brain. We took advantage of the naturally occurring difference in psychostimulant sensitivity in DBA/2 mice and selected animals displaying extremes in behavioral sensitization to amphetamine. Subsequently, the dopamine output areas prefrontal cortex (PFC), nucleus accumbens (NAc) and the cornu ammonis 1 (CA1) area of the hippocampus were isolated by laser microdissection and subjected to DNA microarray analysis 1 hour after a challenge dose of amphetamine. A large number of genes with differential expression between high and low responders were identified, with no overlap between brain regions. Validation of these gene expression changes with quantitative RT-PCR demonstrated that the most robust and reproducible effects on gene expression were in the CA1 region of the hippocampus. Interestingly, many of the validated genes in CA1 are members of the CRE-family and appeared to be targets of the glucocorticoid receptor (GR) and myocyte enhancer 2 (Mef2) transcription factors. We hypothesize that CRE, Mef2 and GR signaling form a transcription regulating network, which underlies differential amphetamine sensitivity and therefore may play an important role in susceptibility to psychosis.
INTRODUCTION

Psychosis is characterized by a gradual loss of contact with reality, progressing from emotional instability, acoustic and visual disturbances, decreased discriminative ability for real and surreal ideas and memories to more pronounced symptoms like hallucinations, delusions and thought disorders. Psychotic-like symptoms can be induced by psychostimulant drugs like amphetamine (Janowsky and Risch, 1979). Patients with a high susceptibility for psychosis, such as schizophrenia patients, display an increased sensitivity to amphetamine (Strakowski et al, 1997), that resembles the behavioral sensitization found in rodents after repeated exposure to amphetamine (Alessi et al, 2003; Peleg-Raibstein et al, 2008; Peleg-Raibstein et al, 2006; Tenn et al, 2003). This behavioral sensitization is characterized by a progressive and persisting increase in the behavioral activity and neurochemical responses to psychostimulants, such as stimulation of locomotor activity, stereotypy and dopamine release in the striatum (Featherstone et al, 2007; Laruelle and Abi-Dargham, 1999; Morrens et al, 2006). Moreover, the number of dopamine (DA) D2 receptors in the high-affinity conformational state is altered in the striatum whereas the total expression of DA D2 receptors is not changed in both sensitized animals and schizophrenia patients (Seeman et al, 2007; Seeman et al, 2005). Substantial interindividual differences exist in susceptibility to develop psychosis as well as in sensitivity to amphetamine (Alessi et al, 2003). It has been hypothesized that individuals that are more sensitive to amphetamine are also more susceptible to become psychotic (Post, 1992; Segal et al, 1981). Based on these similarities, the amphetamine-sensitization model can be considered a promising animal model to study several aspects of schizophrenia (Featherstone et al, 2007).

Persistent neuroplastic alterations in the reward circuitry, in particular in the mesolimbic dopamine pathway, are associated with the expression of behavioral sensitization (Nestler, 2005a). The mesolimbic dopaminergic pathway originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc), amygdala, prefrontal cortex (PFC) and other forebrain regions including the cornu ammonis 1 (CA1) subregion of the hippocampus (Floresco et al, 2001; Gasbarri et al, 1994; Thierry et al, 2000). Induction and expression of behavioral sensitization to psychostimulants is a complex process in which various neurotransmitters, in particular dopamine and glutamate, result in downstream molecular adaptations in the VTA-NAc circuitry and other limbic brain regions. In the VTA enhanced glutamatergic neurotransmission results in a sensitized state resembling long-term potentiation (LTP). In the NAc, induction of the transcription factors ΔFosb and CREB appear to be common adaptations in response to chronic exposure to drugs of abuse, contributing to the sensitized state (McClung and Nestler, 2003; McClung et al, 2004; Nestler, 2005b; Shaw-Lutchman et al, 2003). In addition, the ERK pathway and cAMP-independent activation of Akt-GSK3 may also play a role in long-lasting behavioral sensitization (Beaulieu et al, 2007; Emamian et al, 2004; Valjent et al,
However, still a lot remains unresolved regarding the molecular events that contribute to behavioral sensitization in different brain regions of the mesolimbic dopamine circuitry.

The aim of the current study was to investigate which genes and pathways may contribute to behavioral sensitization in different parts of the mesolimbic circuitry in the mouse brain. We hypothesize that the same genes and pathways underlying behavioral sensitization are also involved in the vulnerability to psychosis. To investigate these molecular pathways we took advantage of the naturally occurring variability in behavioral sensitization to amphetamine in DBA/2 mice, an inbred mouse line (de Jong et al, 2007), thus ruling out the influence of genetic differences. We developed a sensitization regimen that allowed us to separate mice in two distinct groups showing very high sensitization and no sensitization to amphetamine, respectively, despite the exact same amphetamine treatment. Large scale gene expression profiles were generated of several dopaminergic output brain regions, including the CA1 region of the hippocampus, the NAc and PFC, in mice selected for extremes in behavioral sensitization to amphetamine, in search of susceptibility genes and pathways underlying the differential behavioral sensitization.
MATERIALS & METHODS

Drugs  D-amphetamine (\(+\)-a-methylphenethylamine sulfate; Unikem A/S, Copenhagen, Denmark) was dissolved in 0.9% sodium chloride. Doses are listed as salt equivalents (mg/kg).

Animals  Animal experiments were in accordance with the guidelines issued by the Danish Animal Experimentation Inspectorate. DBA/2 mice (Charles River Laboratories, Salzfeld, Germany) were housed 4 mice per cage in a temperature and humidity controlled environment at a 12 hour light-dark cycle. During the experiment animals had ad libitum access to water and food. Mice were left undisturbed for 14 days prior to initiation of the experiments.

Amphetamine sensitization  In experiment 1 mice were divided in four groups based on the treatment received during days 1-5 and on day 20 respectively: group 1 (amph/amph, n=100), group 2 (sal/sal, n=10), group 3 (sal/amph, n=10) and group 4 (amph/sal, n=10). Animals received either d-amphetamine (2.5 mg/kg) or saline for 5 consecutive days (days 1-5). After a 14 day withdrawal period, animals were given a low dose amphetamine challenge (1.25 mg/kg) or saline (day 20) (For a detailed scheme see Figure 1). At the drug challenge (day 20), locomotor behaviour was assessed as described below. Based on the locomotor response to the amphetamine challenge on day 20, the 10% amph/amph animals with the highest locomotor response were designated high responders (HR) (n=10), while the 10% animals with the lowest response were designated low responders (LR) (n=10). The high and low responders were used for subsequent gene expression analysis.

A) GENE-EXPRESSION STUDY  

| Time (days) | 1 | 2 | 3 | 4 | 5 |
|-------------|---|---|---|---|---|
| 2.5 mg/kg amph or saline | Selection population extremes | 20 |

Challenge 1.25 mg/kg amph or saline  
Locomotor Test  
Sacrifice 1 hr post challenge

B) PHENOTYPIC STABILITY  

Population extremes (selected on day 20)  
27  
Challenge (2) 1.25 mg/kg amph  
Locomotor Test  
Sacrifice 1 hr post challenge

Figure 1A | Animals received either d-amphetamine (2.5 mg/kg) or saline for 5 consecutive days (days 1-5). After a 14-day withdrawal period (day 20) animals were given a low dose amphetamine challenge (1.25 mg/kg) or saline and the 10% population extremes in the AMPH/AMPH group (low and high responders) were selected. In the expression profiling study, mice were sacrificed 1 hour after the challenge on day 20 (experiment 1).B | In the follow-up study (experiment 2), the low and high responders received an additional amphetamine (1.25 mg/kg) challenge on day 27 and were sacrificed 1 hour later. Locomotor tests were performed on the indicated days.

In a follow-up experiment (experiment 2) it was investigated whether the HR and LR phenotype is stable. A new batch of animals was subjected to the same treatment and dosing regimen as in the
first study. The selected 10% HR and LR responders of the amph/amph group (n=10 each) on day 20 were subsequently left undisturbed for an additional 7 days and re-challenged with 1.25 mg/kg on day 27 and locomotor behavior was measured again (Figure 1). The HR and LR responders were used for revalidation of gene expression changes measured in experiment 1.

**Locomotor behaviour** Animals were placed individually in makolon locomotor activity cages (20 cm × 35 cm × 18 cm) (Lundbeck). Following a 60 minute habituation period, amphetamine or vehicle was administered and locomotor activity was recorded for an additional 60 min. The locomotor activity cages were equipped with 5 × 8 infrared light sources plus photocells. The light beams crossed the cage 1.8 cm above the bottom of the cage. During the test session, locomotor activity was recorded as crossings of infrared light beams, and total locomotor count represents the accumulated number of crossings over the 60 minute period. The recording of a motility count required interruption of two adjacent light beams, thus avoiding counts induced by stationary movements of the mice. All experiments were conducted during the light phase of the cycle and initiated using a clean cage.

**Tissue dissection** Selected mice were sacrificed directly after the locomotor activity measurement on day 20 (experiment 1) and on day 27 (follow-up experiment 2). Brains were rapidly dissected and snap-frozen in isopentane (cooled in ethanol placed on pulverised dry ice) and stored at -80C for later use.

**Brain amphetamine levels** Amphetamine in total brain homogenates was measured in two groups (n=10 each) of mice with locomotor activity counts just below the highest and just above the lowest responders. Amphetamine levels were measured by liquid chromatography/tandem mass spectrometry (LC–MS/MS) to test whether differences in responsiveness could be accounted for by differences in brain drug exposure. Brain tissue was homogenated with four times its weight of Acetonitrile:water (70:30) using a TomtecAutogizer. The supernatant was analyzed like plasma. On line sample preparation and liquid chromatography were performed with turbulent flow chromatography (Cohesive Technologies, UK), using a dual column configuration. MS/MS detection was done with an Applied BiosystemsSciex API 3000 instrument in positive-ion electrospray ionization mode.

**Laser microdissection** Laser microdissection (LMD) was performed as previously described (Datson et al, 2004) on brain tissue from experiment 1. Briefly, coronal brain sections (8 μm) were cut using a cryostat (PALM, Bernried, Germany) at -18°C. According to the Mouse Brain Atlas (Franklin, 1997) cryosections from CA1 area were collected starting at Bregma -1.58, NAc cryosections between Bregma +1.70 and +1.18 and PFC cryosections (Prelimbic and Infralimbic cortex) between Bregma +2.80 and +2.10. Both hemispheres were used for sectioning. Cryosections were thaw-mounted on
PEN-membrane slides (1440-1000, PALM, Bernried, Germany) which had been pretreated by heating for 4 hours at 180°C and subsequent UV irradiation for 30 min at 254 nm. After sectioning the slices were kept at -80°C until further use. On the day of LMD, the slides were briefly stained with haematoxylin (10 %) and dehydrated in 70, 95 and 100% ethanol, briefly dipped in xylene and dried at 40°C. Immediately afterwards, the slides were used for LMD and the laser microdissected tissue fragments were collected in adhesive caps (1440-0250 PALM, Bernried, Germany). A conservative estimate of CA1 was taken to avoid contamination with CA2/CA3. For NAc, an area containing both the core and shell was dissected. For PFC both prelimbic and medial orbital cortical regions were combined (Figure 2). Per mouse a total of 4 sections were dissected and pooled to constitute a sample for subsequent linear amplification and microarray hybridization.

Figure 2 | Scheme showing connection between the selected brain areas including examples of laser microdissection. PFC: prefrontal cortex; IL: infralimbic; PL: prelimbic; (NAc) nucleus accumbens; CA1: cornu ammonis 1 region of the hippocampus; VTA: ventral tegmental area. Red arrows indicate glutamatergic neurons, black arrows dopaminergic neurons and blue arrows GABAergic neurons. Glu: glutamate; DA: dopamine; GABA: gamma-aminobutyric-acid.
RNA isolation, linear amplification and microarray hybridization Immediately after laser microdissection, RNA was isolated using Trizol (15596-026, Invitrogen Life Technologies, Carlsbad) using the manufacturer’s protocol. Linear acrylamide was added as a carrier. RNA quality and quantity was checked by analyzing 1 μl of RNA on the Agilent 2100 Bioanalyzer using the RNA 6000 Pico LabChip Kit (5065-4473, Agilent Technologies, Palo Alto, USA). Ten ng of total RNA was used for the first round of linear amplification using the GeneChip One-Cycle Target Labeling and Control reagents (P/N 900493, Affymetrix, Santa Clara, USA). For the second round of amplification 100 ng of input RNA was used, during which the RNA was biotin-labeled using the GeneChip Two-Cycle target Labeling and Control Reagents (P/N 900494, Affymetrix, USA).

GeneChip hybridization Twenty micrograms of biotinylated RNA was subsequently fragmented using DNA Fragmentation Reagents (No. AM8740, Ambion). The biotinylated and fragmented RNA was hybridized to GeneChip Mouse Genome 430 2.0 arrays (Affymetrix), containing approximately 45,000 probe sets representing 39,000 transcripts and 35,000 different genes. Hybridizations were conducted at the Leiden Genome Technology Center (LGTC, Leiden University, The Netherlands) according to the manufacturer’s recommendations (Affymetrix, Santa Clara, USA). A total of 60 microarrays were hybridized, per brain region 10 HR and 10 LR.

Data Analysis Raw images were analyzed and features extracted using Affymetrix Gene Chip Operating Software (GCOS) (Affymetrix, Foster City, CA). For each brain region, the resulting CEL files containing probe level information were then normalized and converted to gene intensity values by the GC-RMA algorithm within BRB Arraytools version 3.7.3 developed by Dr. Richard Simon and the BRB Array development team (Simon et al, 2007). To identify differentially expressed genes we applied a two-sample t-test (fold-change>1.2 and p-value cutoff of p<0.01) comparison between high to low responders. Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, www.ingenuity.com) version 7.5 was used to identify pathways, networks and gene-list matching to published datasets of genes involved in specific transcription regulation systems (MEF, CRE, GR). The gene lists for the specific transcription regulation systems were retrieved from the supplementary material in the relevant publications (Pfenning et al, 2007; Wu and Xie, 2006; Zhang et al, 2005) and loaded into Ingenuity as comparison datasets.

Real time quantitative PCR (RT-qPCR) Primers for RT-qPCR validation were designed within the target sequence used by Affymetrix for probe design using Primer3 freeware. Primers were checked for specificity using BLAST (NCBI, Bethesda, USA) and for hairpins and self-complementarity using oligo 4.0 (MBI, Cascade, USA). The primer sequences of the validated genes that were measured can
be found in Supplementary Table SI. RT-qPCR measurements were performed on amplified RNA from experiment 1 to replicate the results from the GeneChip analysis. cDNA synthesis was performed using the iScript™ cDNA Synthesis Kit (170-8897, Bio-Rad, Hercules, USA) following the manufacturer’s protocol. RT-qPCR was performed on a Lightcycler 2.0 Real-Time PCR System (Roche Applied Science, Basel, Switzerland) using the Lightcycler FastStart DNA MasterPLUS SYBR Green I Kit (Roche). The standard curve method was used to quantify the expression differences (Livak and Schmittgen, 2001). The non-parametric Mann-Whitney Test was used to assess significant differential gene expression between low and high responders.

Brain tissue from follow-up experiment 2 was used to replicate the changes in gene expression between low and high responders found in the CA1 area in an independent experiment. For this purpose, the dorsal hippocampus was dissected from frozen brain and 8 punches containing CA1 tissue were obtained from two 1mm tissue sections. RNA was synthesized to cDNA without further amplification and RT-qPCR and data analysis was performed as previously reported (Christensen et al) on a selection of genes that were successfully validated in experiment 1.
RESULTS

DBA/2 mice display large and stable individual differences in sensitization to amphetamine The locomotor responses to the challenge dose of amphetamine (1.25 mg/kg) or saline on day 20 are depicted in Figure 3a. On average, animals that received amphetamine pretreatment on days 1-5 (amph/amph) were more responsive to the acute amphetamine challenge than saline pre-treated mice (sal/amph), signifying the occurrence of sensitization. However, a large inter-individual variability was observed in the amph/amph group. The 10% amph/amph animals with highest locomotor response to amphetamine on day 20 were designated high responders (HR) (n=10), while the 10% animals with the lowest response were designated low responders (LR) (n=10). In an independent follow-up study it was demonstrated that the high and low responder phenotype is stable until at least one week after the first drug challenge (Figure 3b). The slight increase in both groups might signify further incubation of sensitization which is known to occur with prolonged withdrawal periods.

![Figure 3A](image_url)  
**Figure 3A** Locomotor responses to the amphetamine (1.25 mg/kg) or saline challenge on day 20. Data are represented as total activity count over the 60 minute treatment period. SAL/SAL n=10, SAL/AMPH n=10, AMPH/SAL n=10, AMPH/AMPH n=100. Ovals indicated the 10% population extremes (low responders n=10, high responders n=10) in the AMPH/AMPH group selected for gene-expression profiling.

![Figure 3B](image_url)  
**Figure 3B** Stability of low and high responder phenotype during challenges at day 20 and 27. Data are represented as total activity count over the 60 minute treatment period. Low responders n=10, high responders n=10. *** p<0.001 vs low responders (Mann-Whitney Rank Sum Test).
**Amphetamine exposure is not different in high and low responders** Amphetamine in total brain homogenates was measured in two groups (n=10 each) of mice with locomotor activity counts just below the highest (21289±377 counts) and just above the lowest responders (4387±406 counts). There was no correlation between exposure and locomotor activity (Supplementary data, Figure S1), indicating that the phenotypic difference in locomotor sensitization could not be attributed to differences in CNS amphetamine exposure.

**Identification of differentially expressed genes reveals region-specific molecular signatures** To identify potential molecular changes induced by the behavioural sensitization microarray analysis was performed on PFC, NAc and hippocampal CA1 regions collected from 10 HR and 10 LR animals 1 h after a challenge dose of amphetamine on day 20 (Figure 1). This time point was selected in order to examine the early factors behind the long-term changes induced by the challenge stimulus and more importantly, to look under challenged conditions in which the differences between HR and LR are most evident. Differentially regulated genes were identified by statistically comparing GC-RMA mean normalized values of HR to LR. Of the 45,000 probes on the Affymetrix gene chip mouse genome 430 2.0 arrays, we identified 63 (39 up, 24 down), 29 (20 up, 9 down) and 105 (76 up, 29 down) genes that significantly differed in expression between HR and LR in CA1, NAc and PFC respectively by two sample t-test (p<0.01, fold-change>1.2) (Figure 4a). These gene lists are referred to as the primary lists (Supplementary material, Table SII). Comparison of the three primary lists revealed no overlapping genes (Figure 4b). Moreover, pairwise correlation analysis of all expression values in the 60 samples showed a clear distinction in region specific expression signatures (Figure 4c). These specific molecular signatures of the analysed brain regions most likely reflect both their specific connectivity and function in a complex circuit as well as their distinct molecular response to amphetamine challenge.

**Differential expression between HR and LR was most robust in the hippocampal CA1 region** A total of 83 genes were selected for reconfirmation by RT-qPCR from all three brain regions based on overall lowest p-value and highest fold change. In both NAc and PFC the reconfirmation rates were rather low, with a reconfirmation rate of 3 out of 24 genes (12.5%) in the NAc and 5 out of 30 genes (16.7%) in the PFC. In the CA1 the reconfirmation rate was considerably higher, with a success rate of 14 out of 28 genes (50.0%).
Figure 4A | Volcano plots of -log10 (p-value) vs. log2(Fold change). Labeled are largest fold change and lowest p-value genes. The blue points in each graph indicate the Affymetrix probesets that passed the t-test p<0.01 and FC>1.2 statistical requirements. B: Venn diagram of genes differentially expressed between HR and LR. Genes meeting the F>1.2 fold, p<0.01 criteria have been included. No common genes are identified when comparing CA1, PFC and NAc. C: Correlation matrix of expression levels between all 60 samples in the experiment. Differential expression between tissues is clearly identified. Correlation analysis is not able to differentiate between high and low responder groups.
Gene expression changes in CA1 could be replicated in a novel independent study. The expression of several genes that were confirmed to show differential expression in the CA1 area with RT-qPCR in the first experiment were validated in an independent sensitization experiment. Gene expression of six selected genes (Arc, Nr4a1, Dusp1, Fos, Egr2 and Tiparp) was quantified in the CA1 of the phenotypically stable animals that received a second amphetamine challenge (Figure 1). In contrast to the validation described above, the six genes were measured in non-amplified mRNA derived from manually dissected CA1 rather than laser microdissection. Despite these technical differences the results replicated the differential expression between LR and HR that was shown in the first study, although NR4a1 did not reach statistical significance (Figure 5).

![Gene expression graphs](image-url)

Figure 5 |RT-qPCR validation results of gene expression differences between low and high responders in the CA1 region of the hippocampus in the second animal experiment. ** p<0.01 vs low responders; *** p<0.001 vs low responders (Mann-Whitney Rank Sum Test)
Validated genes overlap with several gene classes, including GR, MEF2, and CRE regulated genes. The genes differentially expressed in CA1 were subjected to Ingenuity Pathway Analysis (IPA). Genes regulated by specific transcription factors or promoter systems as identified by ChIP/ChIP technology were identified from the literature and used to compose gene lists for target genes of transcription factors MEF2, CREB, GR and REST (Supplementary material, Table SIII for details). Each of the gene lists were compared to the 63 genes identified in CA1 and to a list of 2000 randomly selected genes from the entire list of probe sets (~45,000 probes). This comparison indicated a clear overrepresentation of GR, CRE and MEF2 promoter regulated genes among the differentially regulated gene set in CA1 (Figure 6). The comparison was repeated with a large number of randomizations of the R2K set and the differences shown in Figure 6 were found to be stable.

Transcription factor analysis

Figure 6 | Comparison of genes regulated in CA1, Nucleus Accumbens (Acc) and Prefrontal Cortex (PFC) to genes involved in specific transcriptional regulation as identified by ChIP/ChIP experiments. For each of the brain areas the comparison is made for the genes identified in expression array and for those confirmed by qPCR. The R2K dataset represents 10 x 2000 random probe sets, indicating background signal and size difference of ChIP/ChIP data sets used. Genes compared are those listed in supplementary Table I, and shown in figure 4. qPCR confirmed genes are those genes from gene expression data set that were confirmed by qPCR with a p-value better than 0.05 in any of the validation experiments (Sup Table III).
DISCUSSION

The aim of this study was to elucidate which genes and pathways underlie the differences in behavioral response to amphetamine in genetically identical mice selected for responsiveness to amphetamine sensitization. The amphetamine sensitization model is suggested to reflect the heightened sensitivity of schizophrenia patients to psychostimulants and is accepted as a model for the positive symptoms observed in schizophrenia (Featherstone et al, 2007; Hermens et al, 2009; Peleg-Raibstein et al, 2008; Peleg-Raibstein et al, 2009; Tenn et al, 2003). Additionally, there is increasing evidence for long-lasting cognitive deficits in sensitized animals (Featherstone et al, 2007). In this study we used a unique setup based on genetically identical inbred mice, all receiving the same treatment yet still displaying differences in amphetamine-sensitization. This is an important divergence to most studies reporting on gene expression focusing on differences in outbred strains and/or differences in treatment (e.g. control vs. amphetamine or acute vs. chronic amphetamine) (Funada et al, 2004; Palmer et al, 2005; Shilling et al, 2006; Sokolov et al, 2003). By taking this approach we are ruling out changes in gene regulation due to variation in genetic makeup and different treatment paradigms. Thus, the differential gene regulation found in the present study is most like reflecting the underlying mechanism for sensitization and may point to why some individuals get schizophrenia whereas others do not.

Largest effect of sensitization on gene expression was found in the CA1 area of the hippocampus

We observed a considerable variation in sensitization to amphetamine in DBA/2 mice measured by locomotor output. Gene expression in CA1, NAc and PFC, all dopaminergic output brain areas, of the 10 lowest and 10 highest responders (LR and HR) was assessed 1 hour after amphetamine challenge. Gene expression signatures were highly brain region-specific, with the strongest differential expression between low and high responders in the CA1 subregion of the hippocampus. These findings are of interest since most research on amphetamine-induced gene expression so far has focused on PFC, Striatum, NAc and VTA (Mirmics et al, 2000; Palmer et al, 2005; Yuferov et al, 2005). However, our data are consistent with recent literature pointing to a prominent role of the hippocampus and dopamine in schizophrenia (Grace, 2010; Lisman and Grace, 2005; Lodge and Grace, 2007, 2008; Rossato et al, 2009), for review see (Shohamy and Adcock, 2010). In schizophrenic patients and high-risk individuals there is elevated regional cerebral blood volume (rCVB) in the CA1 sub-region of hippocampus, which correlates with positive symptoms and predicts clinical progression (Gaisler-Salomon et al, 2009b; Schobel et al, 2009). The increased hippocampal activity linked to psychotic symptoms is in line with data by Grace et al. showing how the hippocampus controls dopamine (DA) neuron activity, possibly by increasing the number of DA neurons that can be activated by salient signals (Grace et al, 2007). In contrast, antipsychotic phenotype measured as
reduced amphetamine-induced locomotion and release of dopamine in NAc is seen in an animal model with reduced glutaminase activity leading to a CA1/subiculum-specific decrease in rCVB(Gaisler-Salomon et al, 2009a).

Furthermore, preventing synaptic transmission in the dorsal region of the hippocampus by local infusion of the anaesthetic lidocaine is able to block the expression of behavioral sensitization to amphetamine (Beck et al, 2009). Finally, Crombag et al. showed that amphetamine self-administration leads to increased spine-density in the CA1 region of the hippocampus (Goeman et al, 2004). Although, not investigated in the current study changes in spine morphology may likely be present in our sensitized mice. The differences in expression of Mef2 target genes we identified fit well with a potential difference in spine-density, given that Mef2 is a key regulator of neuronal plasticity and that manipulating Mef2 expression and activity directly influences psychostimulant sensitization (Pulipparacharuvil et al, 2008).

We cannot draw any conclusions on the role of other dopaminergic brain regions that are of relevance to the development of behavioral sensitization, e.g. the VTA or the amygdala (Yuferov et al, 2005). It is possible that they may harbor bigger differences in gene expression than currently observed in CA1. However, that would need to be addressed in a follow-up study.

**Immediate early genes** Many of the validated genes are immediate early genes (IEGs), which are among the first genes to be expressed (hence the name) in a changing environment. Examples of IEGs identified in this study are c-fos, Dusp1, Nr4a1, Egr2, Arc and Tiparp. Other studies have also found IEGs to be responsive to amphetamine in the brain. For example, Shilling et al showed down-regulation of several IEGs in the PFC of HR 24 hours after a single injection of methamphetamine (Shilling et al, 2006). Down-regulation of IEGs at such a late time point may represent an adaptive response to counterbalance the earlier increase in IEG expression as observed in the present study. One of the IEGs we found to be up-regulated in the HR is c-fos. Interestingly, Zhang et al found that c-fos down-regulation in DA D1 receptor containing neurons attenuates cocaine-induced behavioral sensitization (Zhang et al, 2006). This might indicate that higher c-fos expression in the HR is a cause rather than a consequence of the observed increased locomotor response to amphetamine. In line with our findings for c-fos, two independent studies show that methamphetamine increases expression of IEG Arc from 1 hour onwards in multiple brain regions, which can be blocked by giving a D1 receptor antagonist (Kodama et al, 1998; Yamagata et al, 2000). Since many IEGs are regulated by multiple transcription factors, the question rises what the link is to the underlying mechanisms of amphetamine sensitivity.
GR, Mef2 and Creb are important regulators of sensitization We found a clear overrepresentation of GR, Mef2 and CRE promoter regulated genes among the differentially regulated gene set in CA1 (Figure 6). These transcription factors are interesting candidates linking the regulation of IEGs to mechanisms of behavioral sensitization and psychosis susceptibility.

Glucocorticoids GR, an important receptor for glucocorticoid stress hormones in the brain, is a transcription factor that is able to regulate many of the IEGs as well as some of the other validated genes that were differentially expressed between high- and low-responders in CA1. Stress and more particular glucocorticoids are factors influencing sensitization to psychostimulants (Antelman et al, 1980). We have previously shown that cocaine sensitization in DBA/2 mice relies in part on corticosterone (de Jong et al, 2007). Moreover it was shown that antagonizing GR attenuates the expression of amphetamine-induced sensitization (De Vries et al, 1996). Also in humans, many studies have shown that psycho-stimulant abuse and stressful life events are associated with later-life psychotic episodes, with odds ratios even increasing with cumulative traumas (Johns et al, 2004; Shevlin et al, 2008; Wiles et al, 2006).

In rodents a similar link between stress, glucocorticoids and behavioral sensitization was found. Chronic social stress increased amphetamine-induced locomotion (Mathews et al, 2008) and vice versa (Antelman et al, 1980; Myin-Germeys and van Os, 2007; Vanderschuren et al, 1999). Withdrawal from amphetamine leads to increased corticosterone levels in rats that show sensitization but not in non-sensitized animals (Scholl et al, 2009). DBA/2 mice are known for their vulnerability to stressful events (Weaver et al, 2004). Our findings indicate that several of the genes that are differentially expressed between LR and HR are involved in glucocorticoid signaling. For example, Nr4a1 was one of the IEGs we identified to have a higher expression in the CA1 of HR. Nr4a1 belongs to the family of orphan nuclear receptors and is also increased by amphetamine in the striatum (Levesque and Rouillard, 2007). Nr4a1 is known to bind to NGFI-B sites in addition to glucocorticoid response elements (GREs). It has been shown that Nr4a1 can compete with the GR for binding to a negative GRE (nGRE) sequence on the POMC promoter in the hypothalamus, preventing the GR-induced inhibition of ACTH (Okabe et al, 1998; Philips et al, 1997), which is part of the negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis and vital for proper functioning of the stress system. Several other of the differentially expressed genes we identified are glucocorticoid-responsive, such as for example Dusp1 (King et al, 2009). Hippocampal Dusp1 expression is known to be induced by glucocorticoids (Morsink et al, 2006), suggesting that high responders have an increased corticosterone response to the amphetamine challenge, corresponding to a sensitized HPA-axis.
MEF2 The transcription factor Mef2 plays a role in regulation of IEGs and behavioral sensitization. MEF2 is a key regulator of structural synapse plasticity and has recently been implicated in behavioral sensitization to cocaine (Flavell et al, 2008; Livak et al, 2001). Chronic cocaine treatment was shown to affect Mef2 phosphorylation in the NAc, thus altering its activity (Pulipparacharuvil et al, 2008). Mef2 is phosphorylated and consequently inhibited by Cdk5 in combination with its activators p35 and p25 (Gong et al, 2003). P25 protein level, responsible for a prolonged activation of Cdk5, was shown to be increased 4 hours after acute or chronic amphetamine treatment (Mlewski et al, 2008) and might explain the altered activity of Mef2 during psychostimulant sensitization. Expression of Cdk5 itself can be directly regulated by ΔFosB (Kumar et al, 2005), that in turn is increased after psychostimulant treatment and can remain elevated for weeks (Nestler, 2005b). Cdk5 not only phosphorylates Mef2 but was also found to phosphorylate GR in a dexamethasone-dependent manner (Kino et al, 2007). Consequently, amphetamine-induced changes in Cdk5 may affect both GR and Mef2 transcriptional activity. This suggests that the glucocorticoid stress system and Mef2-driven pathways converge, and would provide an explanation for how individual differences in stress can affect the sensitization process. Interestingly, Mef2 expression itself was not found to be different between low- and high-responders.

CREB (cAMP response element-binding). We found that cAMP response element (CRE)-family transcription factors overall can affect at least 15% of qPCR confirmed AMPH-regulated genes in CA1 (Figure 6). In a random set of genes picked from the gene expression chip this number is low (3.4%, see Figure 6). This CRE-family transcription factor overrepresentation is in line with the literature. The CREB protein is a transcription factor that binds to CRE DNA signature sequences and, thereby, increases or decreases the transcription of downstream genes (Purves D, 2008). Genes relevant for amphetamine sensitization and dopamine function whose transcription is regulated by CREB include: c-fos, BDNF, tyrosine hydroxylase (TH), and many neuropeptides (such as somatostatin, enkephalin, VGF, and corticotropin-releasing hormone) (Purves D, 2008). CREB has a well-documented role in neuronal plasticity and long-term memory formation in the brain (Silva et al, 1998).

Environmental factors Since all mice from this inbred strain received an identical treatment, a plausible underlying cause for difference in sensitization may be that differences in handling, social hierarchy or maternal care underlie the differential expression of amphetamine sensitivity via effects on the glucocorticoid stress system (Badiani et al, 1992; Holmes et al, 2005; Lockwood and Turney, 1981). This fits well with the numerous studies pointing to an association between early childhood trauma, parental care and social adversity and the later development of psychotic illness (Janssen et al, 2004; Morgan and Fisher, 2007; Morris et al, 2006; Wicks et al, 2005). The stress-system may be
an important biological mechanism linking sensitization processes initiated by developmental stress exposures to an increased risk for psychosis. Recent studies have shown changes in cortisol secretion associated with smaller left hippocampal volume in first-episode psychosis patients (Mondelli et al, 2010b) and a blunted cortisol awakening response compared with controls (Mondelli et al, 2010a) and increased emotional reactivity to stress in daily life (Lataster et al, 2009).

**Technical considerations** In the current study we demonstrated that there are individual differences in gene expression in key dopaminergic output areas in the brain that reflect a differential sensitivity to amphetamine. Differences in gene expression in all 3 brain regions were subtle, with the majority of gene expression changes being below 1.5-fold. These modest changes in gene expression are not surprising, given that low and high responders have the same genetic background and received an identical sensitization protocol using exactly the same amphetamine dosing regimen. Nonetheless, our setup using laser microdissection in combination with DNA microarrays is evidently sensitive enough to detect these changes. Validation of the identified gene expression changes proved to be difficult, in particular in the NAc and PFC. Validation of subtle differences in gene expression by other methods such as RT-qPCR is notoriously difficult, due to limitations in sensitivity. Most commonly, a 2-fold change is reported as the cutoff below which microarray and qPCR data begin to lose correlation. Dallas et al. reported decreased correlations for genes expressing less than 1.5-fold change using qPCR and oligonucleotide microarrays (Dallas et al, 2005). Nonetheless, we were able to validate 22 out of 87 genes with RT-qPCR, with the highest success rate (50%) in the CA1 region of the hippocampus.

**Sources of experimental uncertainty** We have a high level of confidence in our CA1 array data for the following reasons. First, the genes identified here are based on strong statistical comparisons with ten biological replicates in each group, decreasing the probability of false negatives. This is in contrast to a majority of published reports where either small numbers of animals are used in each comparison group or technical replicates of pooled animals are applied to identify target genes (Pawitan et al, 2005). Second, rather than using a whole hippocampus homogenate we specifically isolated the CA1 pyramidal cell layer, resulting in a more homogeneous population of neurons highly enriched for CA1 pyramidal neurons and therefore more likely to yield a transcriptional response that is undiluted by effects in other parts of the hippocampus, non-neuronal cells such as glia and isolation artefacts. We have previously demonstrated that the different subregions of the hippocampus differ profoundly in basal transcriptome, demonstrating that in the brain specific isolation and analysis of homogeneous neuronal subpopulations is of utmost importance (Datson et al, 2004; Datson et al, 2009). Third, the validation rate was high considering the small differences in expression. Finally, RT-qPCR re-measurement of representative genes in an independently performed
follow-up experiment demonstrated that the changes in gene expression in CA1 were reliably reproduced and correlated with the high or low responder phenotype.

**Timing** The time at which the gene expression changes were measured in the current study, i.e. 1 hour after an amphetamine challenge, is a point of consideration. Our rationale for choosing this time point was that we wanted to investigate gene expression between low and high responders under challenged rather than baseline conditions, which we hypothesize is a prerequisite to identify pathways relevant for behavioral sensitization and thus susceptibility for psychosis. Under challenged conditions the phenotypic extremes between low and high responders become evident while under basal conditions there are no apparent differences. Further the current design is appropriate for detecting primary gene responses rather than secondary or even more downstream waves of gene expression. It could be argued that looking at a later time point would give more insight in the long-lasting changes in gene expression rather than in acute changes associated with the amphetamine challenge. Indeed, Cadet et al found differential gene expression in the frontal cortex up to 16 hours after a 40 mg/kg dose of methamphetamine, although this dose is much higher (32-fold higher) compared to the rather low doses given in our study (Cadet et al, 2001). Nonetheless, the success of our approach is evident since the changes in gene expression we identified in CA1 reproducibly discriminate high from low responders, as demonstrated in the independent follow up experiment we performed.
CONCLUSION

In conclusion, we show that inbred DBA/2 mice exhibit large differences in sensitization to amphetamine that is reflected at the transcriptional level in several dopaminergic output brain areas, but in particular in the CA1 area of the hippocampus. We have identified CRE, Mef2 and GR transcription factors as possible mediators of these differences. CRE, Mef2 and GR signaling appears to form a transcription regulation network involved in the amphetamine susceptibility response and thus may play an important role in psychosis susceptibility. To which extent these systems act as independent, linked or sequential programs is the target of future studies.
REFERENCES

Alessi SM, Greenwald M, Johanson CE (2003). The prediction of individual differences in response to D-amphetamine in healthy adults. Behav Pharmacol 14: 19-32.

Antelman SM, Eichler AJ, Black CA, Kocan D (1980). Interchangeability of stress and amphetamine in sensitization. Science 207: 329-331.

Badiani A, Cabib S, Puglisi-Allegra S (1992). Chronic stress induces strain-dependent sensitization to the behavioral effects of amphetamine in the mouse. Pharmacol Biochem Behav 43: 53-60.

Beaulieu JM, Gainetdinov RR, Caron MG (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28: 166-172.

Beck IM, Vanden Berge W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K (2009). Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 30: 830-882.

Cadet JL, Jayanthi S, McCoy MT, Vawter M, Ladenheim B (2001). Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse 41: 40-48.

Christensen KV, Leffers H, Watson WP, Sanchez C, Kallunki P, Egebjer J Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci 11: 9.

Datson NA, Meijer L, Steenbergen PJ, Morsink MC, van der Laan S, Meijer OC, et al (2004). Expression profiling in laser-microdissected hippocampal subregions in rat brain reveals large subregion-specific differences in expression. Eur J Neurosci 20: 2541-2554.

Datson NA, Morsink MC, Steenbergen PJ, Aubert Y, Schlumbohm C, Fuchs E, et al (2009). A molecular blueprint of gene expression in hippocampal subregions CA1, CA3, and DG is conserved in the brain of the common marmoset. Hippocampus 19: 739-752.

de Jong IE, Otzíl MS, de Kloet ER (2007). Adrenalectomy prevents behavioura sensitisation of mice to cocaine in a genotype-dependent manner. Behav Brain Res 177: 329-339.

De Vries TJ, Schoffelmeer AN, Tjorn GH, Nestby P, Mulder AH, Vanderschuren LJ (1996). Mifepristone prevents the expression of long-term behavioural sensitization to amphetamine. Eur J Pharmacol 307: R3-4.

Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131-137.

Featherstone RE, Kapur S, Fletcher PJ (2007). The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 1556-1571.

Flavell SW, Kim TK, Gray JM, Harmin DA, Hemberg M, Hong EJ, et al (2008). Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuro 60: 1022-1038.

Floresco SB, Todd CL, Grace AA (2001). Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 21: 4915-4922.

Franklin KA, G. (1997). The Mouse Brain in Stereotaxic Coordinates, 1 edn. Academic Press: San Diego.

Funada M, Zhou X, Satoh M, Wada K (2004). Profiling of methamphetamine-induced modifications of gene expression patterns in the mouse brain. Ann N Y Acad Sci 1025: 76-83.

Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghodhodossi F, et al (2009a). Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology 34: 2305-2322.

Gaisler-Salomon I, Schobel SA, Small SA, Rayport S (2009b). How high-resolution basol-state functional imaging can guide the development of new pharmacotherapies for schizophrenia. Schizophr Bull 35: 1037-1044.

Gasbarri A, Verney C, Innocenzi R, Campana E, Pacitti C (1994). Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study. Brain Res 668: 71-79.

Goeman JJ, van de Geer SA, de Korst F, van Houwelingen HC (2004). A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 93-99.

Gong X, Tang X, Wiedmann M, Wang X, Peng J, Zheng D, et al (2003). Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuro 38: 33-46.

Grace AA (2010). Dopamine System Dysregulation by the Ventral Subiculum as the Common Pathophysiological Basis for Schizophrenia Psychosis, Psychostimulant Abuse, and Stress. Neurotox Res 18: 367-376.

Grace AA, Floresco SB, Goto Y, Lodge DJ (2007). Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30: 220-227.

Hermens DF, Lubman DJ, Ward PB, Naismith SL, Hickie IB (2009). Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust 190: 522-25.

Holmes A, le Guisquet AM, Vogel E, Millstein RA, Leman S, Belzung C (2005). Early life genetic, epigenetic and environmental factors shaping emotionality in rodents. Neurosci Biobehav Rev 29: 1335-1346.

Janowsky DS, Risch C (1979). Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl) 65: 73-77.

Janssen I, Krabbe Ream, B, M, Hansen M, Vollebergh W, de Graaf R, et al (2004). Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand 109: 38-45.
Johns LC, Cannon M, Singleton N, Murray RM, Farrell M, Brugha T, et al (2004). Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 185: 298-305.

King EM, Holden NS, Gong W, Rider CF, Newton R (2009). Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. J Biol Chem 284: 26803-26815.

Kino T, Ichijo T, Amin ND, Kesavapany S, Wang Y, Kim N, et al (2007). Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol Endocrinol 21: 1552-1568.

Kodama M, Akiyama K, Ujike H, Shimizu Y, Tanaka Y, Kuroda S (1998). A robust increase in expression of arc gene, an effector immediate early gene, in the rat brain after acute and chronic methamphetamine administration. Brain Res 796: 273-283.

Kumar A, Choi KH, Renthal W, Tsankova NM, Theobald DE, Truong HT, et al (2005). Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48: 303-314.

Laruelle M, Abi-Dargham A (1999). Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 13: 358-371.

Lataster T, Wichers M, Jacobs N, Mengelers R, Derom C, Thiery E, et al (2009). Does reactivity to stress cosegregate with subclinical psychosis? A general population twin study. Acta Psychiatr Scand 119: 45-53.

Levesque D, Rouillard C (2007). Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci 30: 22-30.

Lisman JE, Grace AA (2005). The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46: 703-713.

Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) Method. Methods 25: 402-408.

Lockwood JA, Turney TH (1981). Social dominance and stress-induced hypertension: strain differences in inbred mice. Physiol Behav 26: 547-549.

Lodge DJ, Grace AA (2007). Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27: 11424-11430.

Lodge DJ, Grace AA (2008). Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. J Neurosci 28: 7876-7882.

Mathews IZ, Mills RG, McCormick CM (2008). Chronic social stress in adolescence influenced both amphetamine conditioned place preference and locomotor sensitization. Dev Psychobiol 50: 451-459.

McClung CA, Nestler EJ (2003). Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci 6: 1208-1215.

McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ (2004). DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res 132: 146-154.

Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28: 53-67.

Mlewski EC, Krapacher FA, Ferreras S, Paglini G (2008). Transient enhanced expression of Cdk5 activator p25 after acute and chronic d-amphetamine administration. Ann N Y Acad Sci 1139: 89-102.

Mondelli V, Dazan P, Hugul N, Di Forti M, Aas M, D’Albenzo A, et al (2010a). Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res 116: 234-242.

Mondelli V, Pariente CM, Navari S, Aas M, D’Albenzo A, Di Forti M, et al (2010b). Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr Res 119: 75-78.

Morgan C, Fisher H (2007). Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma—a critical review. Schizophr Bull 33: 3-10.

Morrens M, Hulstijn W, Lewi PJ, De Hert M, Sabbe BG (2006). Stereotypy in schizophrenia. Schizophr Res 84: 397-404.

Morris MS, Morey AF, Stackhouse DA, Santucci RA (2006). Fibrin sealant as tissue glue: preliminary experience in complex genital reconstructive surgery. Urology 67: 688-691; discussion 691-682.

Morsink MC, Steenbergen PJ, Vos JB, Karst H, Joels M, De Kloet ER, et al (2006). Acute activation of hippocampal glucocorticoid receptors results in different waves of gene expression throughout time. J Neuroendocrinol 18: 239-252.

Myin-Germeys I, van Os J (2007). Stress-reactivity in psychosis: Evidence for an affective pathway to psychosis. Clin Psychol Rev 27: 409-424.

Nestler EJ (2005a). Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.

Nestler EJ (2005b). The neurobiology of cocaine addiction. Sci Pract Perspect 3: 4-10.

Okabe T, Takayanagi R, Adachi M, Imasaki K, Nawata H (1998). Nur77, a member of the steroid receptor superfamily, antagonizes negative feedback of ACTH synthesis and secretion by glucocorticoid in pituitary corticotrope cells. J Endocrinol 156: 169-175.

Palmer AA, Verbitsky M, Suresh R, Kamens HM, Reed CL, Li N, et al (2005). Gene expression differences in mice divergently selected for methamphetamine sensitivity. Mamm Genome 16: 291-305.

Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A (2005). False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21: 3017-3024.

61
Peleg-Raibstein D, Knuesel I, Feldon J (2008). Amphetamine sensitization in rats as an animal model of schizophrenia. Behav Brain Res 191: 190-201.

Peleg-Raibstein D, Sydekum E, Feldon J (2006). Differential effects on prepulse inhibition of withdrawal from two different repeated administration schedules of amphetamine. Int J Neuropsychopharmacol 9: 737-749.

Peleg-Raibstein D, Yee BK, Feldon J, Hauser J (2009). The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? Psychopharmacology (Berl) 206: 603-621.

Pfenning AR, Schwartz R, Barth AL (2007). A comparative genomics approach to identifying the plasticity transcriptome. BMC Neurosci 8: 20.

Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P, et al (1997). Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol 17: 5952-5959.

Phuc Le P, Friedman JR, Schug J, Brestelli JE, Parker JB, Bochkis IM and Kaestner KH (2005). Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genet 1: e16.

Post RM (1992). Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149: 999-1010.

Pulipparacharuvil S, Renthal W, Hale CF, Taniguchi M, Xiao G, Kumar A, et al (2008). Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neurosci 59: 621-633.

Purves D, Fitzpatrick D, Hall WC, LaMantia AS, McNamara JO, White LE (2008). Neuroscience. Sinauer Associates: Sunderland, pp 170-176.

Rossato JI, Bevilaqua LR, Izquierdo I, Medina JH, Cammarota M (2009). Dopamine controls persistence of long-term memory storage. Science 325: 1017-1020.

Schobel SA, Lewandowski NM, Corcoran CM, Moore H, Brown T, Malaspina D, et al (2009). Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 66: 938-946.

Scholl JL, Feng N, Watt MJ, Renner KJ, Forster GL (2009). Individual differences in amphetamine sensitization, behavior and central monoamines. Physiol Behav 96: 493-504.

Seeman P, McCormick PN, Kapur S (2007). Increased dopamine D2(High) receptors in amphetamine-sensitized rats, measured by the agonist [(3)H](+)-PHNO. Synapse 61: 263-267.

Seeman P, Weinschenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, et al (2005). Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102: 3513-3518.

Segal DS, Geyer MA, Schuckit MA (1981). Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 5: 95-129.

Shaw-Luttmann TZ, Impey S, Storm D, Nestler EJ (2003). Regulation of CRE-mediated transcription in mouse brain by amphetamine. Synapse 48: 10-17.

Shevlina M, Houston JE, Dorathy MJ, Adanson G (2008). Cumulative traumas and psychosis: an analysis of the national comorbidity survey and the British Psychiatric Morbidity Survey. Schizophr Bull 34: 193-199.

Shilling PD, Kuczenski R, Segal DS, Barrett TB, Kelsoe JR (2006). Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine. Neuropsychopharmacology 31: 2359-2367.

Shohamy D, Adcock RA (2010). Dopamine and adaptive memory. Trends Cogn Sci 14: 464-472.

Silva AJ, Kogan JH, Frankland PW, Kida (1998). CREB and memory. Annu Rev Neurosci 21: 127-148.

Simon R, Lam A, Li MC, Ngan M, Menenjes S, Zhao Y (2007). Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 3: 11-17.

So, A. Y., Chaivorapol, C., Bolton, E. C., Li, H. and Yamamoto, K. R. (2007). Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3: e94.

So, A. Y., Cooper, S. B., Feldman, B. J., Manuchehri, M. and Yamamoto, K. R. (2008). Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genes. Proc Natl Acad Sci U S A 105: 5745-5749.

Sokolov BP, Polesskaya OO, Uhl GR (2003). Mouse brain gene expression changes after acute and chronic amphetamine. J Neurochem 84: 244-252.

Strakowski SM, Sax KW, Setters MJ, Stanton SP, Keck PE, Jr. (1997). Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry 42: 749-755.

Tanis KQ, Duman RS and Newton SS (2008). CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry 63: 710-720.

Tenn CC, Fletcher PJ, Kapur S (2003). Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64: 103-114.

Thiery AM, Giovanni Y, Degenetakis E, Glowinski J (2000). Hippocampal-prefrontal cortex pathway: anatomical and electrophysiological characteristics. Hippocampus 10: 411-419.

Valjent E, Corvol JC, Trzaskos JM, Girault JA, Herve D (2006). Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci 7: 20.

Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders FJ, Schoffelmeer AN (1999). A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci 19: 9579-9586.
Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C and Yamamoto KR (2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc Natl Acad Sci U S A 101: 15603-15608.

Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR, et al (2004). Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854.

Wicks S, Hjern A, Gunnell D, Lewis G, Dalman C (2005). Social adversity in childhood and the risk of developing psychosis: a national cohort study. Am J Psychiatry 162: 1652-1657.

Wiles NJ, Zammit S, Bebbington P, Singleton N, Meltzer H, Lewis G (2006). Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br J Psychiatry 188: 519-526.

Wu J, Xie X (2006). Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome Biol 7: R85.

Yamagata K, Suzuki K, Sugiura H, Kawashima N, Okuyama S (2000). Activation of an effector immediate-early gene arc by methamphetamine. Ann N Y Acad Sci 914: 22-32.

Yuferov V, Nielsen D, Butelman E, Kreek MJ (2005). Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 10: 101-118.

Zhang J, Zhang L, Jiao H, Zhang Q, Zhang D, Lou D, et al (2006). c-Fos facilitates the acquisition and extinction of cocaine-induced persistent changes. J Neurosci 26: 13287-13296.

Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, et al (2005). Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102: 4459-4464.
**SUPPLEMENTARY DATA**

Table SI | Sequences of the primers used for validated genes in the three brain areas; CA1, Nac and PFC

| Affymetrix Id | Gene description | Gene symbol | Forward primer sequence | Reverse primer sequence |
|---------------|------------------|-------------|-------------------------|-------------------------|
| 1459698_at    | Unknown          |             | TCGCTGTTGGGTGTTGAAAG    | TTACCCAGGTTGATCTCCAG    |
| 1426719_at/1426720_at | amyloid beta (A4) precursor protein-binding, family B, member 2 | Apbb2 | AACAGGACTGCCAGCACAC  | CCAATGCAAGAGGACAGCAAA   |
| 1418687_at    | activity regulated cytoskeletal-associated protein | Arc | GCTCTAGGCTGTTCCATGA  | CAAGCAGCTACCGAGCAGAAG   |
| 1444667_at    | Bromodomain, testis-specific | Brdt | AGCCCTCCTCCTGACTCCTCCT | AGTAGCATGAGGCCCCAACAC  |
| 1448272_at/1416250_at | B-cell translocation gene 2, anti-proliferative | Btg2 | TGGCTCGTCTCTTCTTCTTCTT | GTGTCGGGACAAAAACACAGA   |
| 1448830_at    | Dual specificity phosphatase 1 | Dusp1 | CAAAATGACTTGACCGCAA | TCACGACCAAGGTTAATCCTC  |
| 1423100_at    | FBJ osteosarcoma oncogene | Fos | AGTCAAGGCTGCTGCTG    | TGGCAACCCAGGTTAATCCTC  |
| 1416155_at    | High mobility group box 3 | Hmgb3 | TGCTAGCAAATCCTGAGTGT | GCAAAACAGGAGGACTCAAG    |
| 1417409_at    | Jun oncogene | Jun | GGTTGGAGGGGTTACAAACT | GGTTGGTGAATTCAAG         |
| 1447308_at    | longevity assurance homolog 5 (S. cerevisiae) | Lass5 | TATTTAATGTTGCTGTTGC    | GCCCTAGGAAGTCCTGACTCAAG |
| 1426850_a_at  | mitogen activated protein kinase kinase 6 | Map2k6 | GCCCTGGTAACAAGGTGCTA | TCGCTAGCAAATCCTGAGTGT | GCAAAACAGGAGGACTCAAG |
| 1436858_at    | Muscleblind-like 2 | Mbnl2 | GCACCATGATCGACAAAC | GCCCTAGGAAGTCCTGACTCAAG |
| 1448645_at    | male-specific lethal-3 homolog 1 (Drosophila) | Msi3l1 | TACTTCCTGTTGGTCTCTGAC | GCCCTAGGAAGTCCTGACTCAAG |
| 1416808_at    | nidogen 1 | Nid1 | CTTCACCTCGACCTGCTAC | GGGTGCAAGGAAAGCTCAAG   |
| 1416505_at    | nuclear receptor subfamily 4, group A, member 1 | Nr4a1 | TATTGAACGTACGTCAGTCT | CCCCATCCTCAACCTTCTCCT  |
| 1422707_at    | phosphoinositide-3-kinase, catalytic, gamma polypeptide | Pik3cg | CGTGAAGAGTGGAGTGAACA | CAGCTAGCGACTCCCTGCTT  |
| 1425059_at    | Protein arginine N-methyltransferase 6 | Prmt6 | GTGCTGAAACCTAGCCCAAAG | GATTGAGTGGTGCTGCTCCT  |
| 1448401_at    | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2 | Smarcd2 | TTGCAATTTACAGGCTCCA | GCCCTGTAAGATGGCAAAA    |
| 1460557_at/1432623_at | Suppressor of var1, 3-like 1 (S. cerevisiae) | Supv3l1 | TCCCTGAACGTCATCAGG | CTGAGGACCTCGAGAAAGGC   |
| 1422570_at    | YY1 transcription factor | YY1 | GCCTGCTTCTTCTTCTTCTC | GCAACTGCACTGAGATTCCCTG  |
No correlation is observed in total brain exposure to amphetamine and locomotor activity of high and low responders to amphetamine.
Table SII | CA1 differentially expressed genes sorted by FC of the univariate test. The 63 genes are significant at the nominal 0.01 level of the univariate test with a fold change cut-off of 1.2. 39 genes are upregulated and 24 downregulated. Note: Comparison is based on high to low responders group

| Probe set   | Description                                      | Gene symbol | FC  | Parametric p-value | Defined Genelist                                      | p-value (10K permutations) |
|-------------|--------------------------------------------------|-------------|-----|---------------------|------------------------------------------------------|---------------------------|
| 1423100_at  | FBI osteosarcoma oncogene                        | Fos         | 2.1 | 2.85E-05            | immunology, tsonc                                    | < 1e-07                   |
| 1416250_at  | B-cell translocation gene 2, anti-proliferative   | Btg2        | 2.0 | 0.0023899           | BTG family proteins and cell cycle regulation        | 0.0017                    |
| 1420136_a_at| NA                                               | NA          | 1.8 | 0.0099056           |                                                      | 0.0102                    |
| 1418687_at  | activity regulated cytoskeletal-associated protein| Arc         | 1.7 | 0.0011492           |                                                      | 0.0013                    |
| 1421811_at  | thrombospondin 1                                 | Thbs1       | 1.7 | 0.0097194           | TSP-1 Induced Apoptosis in Microvascular Endothelial Cell, Cell Communication, ECM-receptor interaction, Focal adhesion, TGF-beta signaling pathway, angiogenesis, cell signaling, immunology, metastasis | 0.005                     |
| 1415899_at  | Jun-B oncogene                                   | Junb        | 1.6 | 0.0010322           | GATA3 participate in activating the Th2 cytokine genes expression, tsonc | 0.0011                   |
| 1448830_at  | dual specificity phosphatase 1                   | Dusp1       | 1.6 | 2.25E-05            | CD40L Signaling Pathway, NFκB activation by Nontypeable Hemophilus influenzae, Regulation of MAP Kinase Pathways Through Dual Specificity Phosphatases, TNFR2 Signaling Pathway, MAPK signaling pathway | 3.00E-04                 |
| 1416505_at  | nuclear receptor subfamily 4, group A, member 1   | Nn4a1       | 1.5 | 0.0005399           | MAPK signaling pathway                               | 6.00E-04                  |
| 1452160_at  | TCDD-inducible poly(ADP-ribose) polymerase       | Tiparp      | 1.5 | 0.0003376           |                                                      | 3.00E-04                  |
| 1415332_at  | zinc finger protein 521                          | Zfp521      | 1.4 | 0.0096931           |                                                      | 0.0093                    |
| 1426721_s_at| TCDD-inducible poly(ADP-ribose) polymerase       | Tiparp      | 1.4 | 0.0014936           |                                                      | 0.0012                    |
| 1448384_at  | protein O-fucosyltransferase 2                    | Pofu2       | 1.4 | 0.00532             |                                                      | 0.0057                    |
| 1418932_at  | nuclear factor, interleukin 3, regulated          | Nfi3        | 1.4 | 0.0057115           | immunology                                           | 0.0064                    |
| 1448722_at  | B-cell translocation gene 2, anti-proliferative   | Btg2        | 1.4 | 0.0010767           | BTG family proteins and cell cycle regulation        | 4.00E-04                  |
| 143025_at   | NA                                               | NA          | 1.4 | 0.0092861           |                                                      | 0.0108                    |
| 1424517_at  | coiled-coil domain containing 12                 | Ccdc12      | 1.4 | 0.0065204           |                                                      | 0.0025                    |
| 1417293_at  | heparan sulfate 6-O-sulfotransferase 1           | Hs6st1      | 1.4 | 0.0059311           | Glycan structures - biosynthesis 1, Heparan sulfate biosynthesis | 0.0077                    |
| 1460257_a_at| 5, 10-methylenetetrahydrofolate synthetase       | Mthfs       | 1.4 | 0.0001039           | One carbon pool by folate                            | 2.00E-04                  |
| 1452161_at  | TCDD-inducible poly(ADP-ribose) polymerase       | Tiparp      | 1.3 | 0.0029702           |                                                      | 0.0016                    |
| 1416122_at  | cyclin D2                                        | Ccnc2       | 1.3 | 0.0096607           | Cyclins and Cell Cycle Regulation, Cell cycle, Focal adhesion, Jak-STAT signaling pathway, Wnt signaling pathway, cell_cycle | 0.0093                    |
| 1415922_at  | zinc finger, MYND domain containing 19           | Zmynd19     | 1.3 | 0.0048729           |                                                      | 0.0027                    |
| 1449851_at  | period homolog 1 (Drosophila)                    | Per1        | 1.3 | 0.0088176           | Circadian Rhythms, Circadian rhythm                  | 0.0089                    |
| 1427405_s_at| RAB11 family interacting protein 5 (class I)     | Rab11fip5   | 1.3 | 0.0020378           |                                                      | 0.0014                    |
| 1428367_at  | N-deacetylase/N-sulfotransferase (heparan          | Ndst1       | 1.3 | 0.0050318           | Glycan structures - biosynthesis 1, Heparan sulfate biosynthesis | 0.0058                    |
| 1441087_at  | RIKEN CDA1 2810011191 gene                        | 2810011191k | 1.3 | 0.0048717           |                                                      | 0.0052                    |
| 1430413_at  | actin binding UM protein family, member 3        | Abim3       | 1.3 | 0.0030014           | Acon guidance                                        | 0.0041                    |
| 1428759_s_at| coiled-coil domain containing 49                 | Cdc49       | 1.3 | 0.0058428           |                                                      | 0.0076                    |
| 1416110_at  | solute carrier family 35, member A4             | Slc35a4     | 1.3 | 0.005264             |                                                      | 0.0064                    |
| 1429210_at  | UBX domain protein 2A                            | Ubxm2a      | 1.3 | 0.0062819           |                                                      | 0.0036                    |
| 1417155_at  | v-my c myelocytomatosis viral related oncogene,   | Myc         | 1.3 | 0.0058435           | tsonc                                                | 0.0076                    |
| Gene ID          | Description                                                                 | Fold Change | p Value |
|-----------------|-----------------------------------------------------------------------------|-------------|---------|
| 1429139_at      | OTU domain containing 78                                                   | 1.2         | 0.004244 |
| 1424214_at      | RIKEN cDNA 9130213B05S locus                                               | 1.2         | 0.002285 |
| 1438751_at      | solute carrier family 30, member 10                                        | 1.2         | 0.008548 |
| 1451264_at      | FERM domain containing 6                                                   | 1.2         | 0.006125 |
| 1429466_s_at    | anterior pharynx defective 1 homolog (C. elegans)                          | 1.2         | 0.002867 |
| 1449886_a_at    | translocase of inner mitochondrial membrane 9 homolog (yeast)              | 1.2         | 0.004809 |
| 1452179_at      | PHD finger protein 17                                                      | 1.2         | 0.0031242|
| 1450227_at      | syndecan 3                                                                 | 1.2         | 0.009391 |
| 1443403_at      | ceramide kinase                                                            | 1.2         | 0.008971 |
| 1428918_at      | SCY1-like 3 (S. cerevisiae)                                                | 0.8         | 0.004804 |
| 1432538_a_at    | replication factor C (activator 1) 3                                      | 0.8         | 0.0043177|
| 1436447_at      | RIKEN cDNA A630026N12 gene                                                 | 0.8         | 0.007991 |
| 1428312_at      | leucine rich repeat containing 57                                          | 0.8         | 0.004858 |
| 1438873_at      | zinc finger protein 38                                                     | 0.8         | 0.0061628|
| 1456948_at      | adaptor-related protein complex AP-4, epsilon 1                            | 0.8         | 0.0021178|
| 1439884_at      | nudix (nucleoside diphosphate linked moiety X)-type motif 16               | 0.8         | 0.0059877|
| 1422570_at      | YY1 transcription factor                                                   | 0.8         | 0.0043526 |
| 1435082_at      | synaptophysin-like protein                                                 | 0.8         | 0.0036971|
| 1435900_at      | expressed sequence C79468                                                 | 0.8         | 0.0018875|
| 1445525_at      | endo/exonuclease endo/nuclease G-like                                      | 0.8         | 0.0093499|
| 1435460_at      | predicted gene, 10004012                                                   | 0.8         | 0.0057281|
| 1457680_a_at    | transmembrane protein 69                                                   | 0.8         | 0.004538 |
| 1440264_at      | NA                                                                         | 0.8         | 0.0072561|
| 1430382_at      | RIKEN cDNA 4833413G10 gene                                                 | 0.8         | 0.0045134|
| 1453024_at      | WD repeat domain 37                                                        | 0.8         | 0.0094737|
| 1449910_at      | RIKEN cDNA 2210418010 gene                                                 | 0.8         | 0.0082338|
| 1441148_at      | NA                                                                         | 0.7         | 0.0086484|
| 1446840_at      | NA                                                                         | 0.7         | 0.0060192|
| 1449872_at      | heat shock protein 3                                                       | 0.7         | 0.009898 |
| 1457757_at      | TOX high mobility group box family member 2                               | 0.7         | 0.0060703|
| 1440222_at      | superoxide dismutase 1, soluble                                           | 0.7         | 0.0043737 |
| 1459958_at      | arginase/serine-rich coiled-coil 1                                         | 0.7         | 0.0023528|
| 1426356_at      | RIKEN cDNA 6330578E17 gene                                                 | 0.6         | 0.0020099|

**Neuroblastoma derived (avian)**

**Gene Expression Analysis**

- The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails
- Free Radical Induced Apoptosis, The IGF-1 Receptor and Longevity, Amyotrophic lateral sclerosis (ALS), Neurodegenerative Disorders, Immunology, Pharmacology

**Significant Genes**

- Neuroblastoma derived domain containing 78
- RIKEN cDNA 9130213B05S locus
- solute carrier family 30, member 10
- FERM domain containing 6
- anterior pharynx defective 1c homolog (C. elegans)
- translocase of inner mitochondrial membrane 9 homolog (yeast)
- PHD finger protein 17
- syndecan 3
- ceramide kinase
- SCY1-like 3 (S. cerevisiae)
- replication factor C (activator 1) 3
- RIKEN cDNA A630026N12 gene
- leucine rich repeat containing 57
- zinc finger protein 38
- adaptor-related protein complex AP-4, epsilon 1
- nudix (nucleoside diphosphate linked moiety X)-type motif 16
- YY1 transcription factor
- synaptophysin-like protein
- expressed sequence C79468
- endo/exonuclease endo/nuclease G-like
- predicted gene, 10004012
- transmembrane protein 69
- NA
- RIKEN cDNA 4833413G10 gene
- WD repeat domain 37
- RIKEN cDNA 2210418010 gene
- NA
- heat shock protein 3
- TOX high mobility group box family member 2
- superoxide dismutase 1, soluble
- arginase/serine-rich coiled-coil 1
- RIKEN cDNA 6330578E17 gene
Table SIII | Gene list sources for IPA Publist analyses

| Study Type/ Database | Factor | Total IPA-mapped Genes | Reference |
|----------------------|--------|-------------------------|-----------|
| In silico            | CRE    | 3445                    | (Zhang et al. 2005) |
| CHIP                 | CRE    |                         | (Tanis et al. 2008) |
| CHIP                 | MEF2   | 107                     | (Flavell et al. 2008, Pulipparacharuvil et al. 2008) |
| CHIP                 | NR-GR  | 445                     | (So et al. 2007, So et al. 2008) |
|                      |        |                         | (Wang et al. 2004, Phuc Le et al. 2005) |